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CC BY-NC-ND license (http://creativeAbstract Gemcitabine is the first-line treatment for pancreatic ductual adenocarcinoma
(PDAC) as well as acts against a wide range of other solid tumors. Patients usually have a good
initial response to gemcitabine-based chemotherapy but would eventually develop resistance.
To improve survival and prognosis of cancer patients, better understanding of the mechanisms
responsible for gemcitabine resistance and discovery of new therapeutic strategies are in great
need. Amounting evidence indicate that the developmental pathways, such as Hedgehog (Hh),
Wnt and Notch, become reactivated in gemcitabine-resistant cancer cells. Thus, the strategies
for targeting these pathways may sensitize cancer cells to gemcitabine treatment. In this re-
view, we will summarize recent development in this area of research and discuss strategies to
overcome gemcitabine resistance. Given the cross-talk between these three developmental
signaling pathways, designing clinical trials using a cocktail of inhibitory agents targeting all
these pathways may be more effective. Ultimately, our hope is that targeting these develop-
mental pathways may be an effective way to improve the gemcitabine treatment outcome in
cancer patients.
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Gemcitabine (20,20-difluoro-20-deoxycytidine; dFdC)1 is a
novel deoxycytidine analogue. Despite of some similarities
with other nucleoside analogues such as cytosine arabino-
side (AraC), gemcitabine has several unique properties and
specific spectrum of activity.2,3 The cytotoxic lesions
caused by gemcitabine include killing cells with active DNA
synthesis (S phase) and blocking cell cycle progression at
the G1/S phase boundary.4 Gemcitabine was originally
used for its antiviral effects but is now widely used as an
anti-cancer chemotherapeutic agent. Gemcitabine is rec-
ommended as a single agent for first-line chemotherapy for
patients with advanced pancreatic cancer.5 It is also used
for chemotherapy for patients with non-small cell lung
cancer,6 breast cancer,7 bladder cancer8 and ovarian
cancer.9
Patients usually have a good initial response to
gemcitabine-based chemotherapy but develop resistance
by time. Gemcitabine resistance can be either intrinsic or
acquired. Resistance can result from molecular and cellular
changes, including nucleotide metabolism enzymes, inac-
tivation of the apoptosis pathway, high expression of drug
efflux pumps, activation of the cancer stem cells or
epithelial-to-mesenchymal transition (EMT) pathway, up-
or down-regulated expression of microRNA (miRNA)
(Fig. 1). It has been demonstrated that pathways such as
Hedgehog (Hh), Wnt and Notch, which regulate embryonic
development and somatic stem cells (SCs), can be reac-
tivated in gemcitabine resistance cancer cells (Fig. 2).
Herein, we will describe recent advances towards targeting
these pathways with a goal to overcome gemcitabine
resistance.Fig. 1 A diagram of gemcitabine metabolism and proposed me
pro-drug that requires cellular uptake and serial phosphorylation t
DNA synthesis and then induce cancer cells apoptosis. Gemcitabine
result from molecular and cellular changes, including nucleotide m
teins, activation of the CSCs and EMT pathway.Gemcitabine metabolism and mechanism of
action
Gemcitabine is transported into cells by sodium-dependent
(concentrative nucleoside transporter hCNTs) and sodium-
independent (equilibrative nucleoside transporter hENTs)
mechanisms.10,11 Once inside the cell, gemcitabine un-
dergoes a series of phosphorylation by deoxycytidine kinase
(dCK) to the monophosphate (dFdCMP) and then by pyrim-
idine nucleoside monophosphate kinase (UMPeCMP kinase)
to give gemcitabine diphosphate (dFdCDP), resulting in
formation of gemcitabine triphosphate (dFdCTP) mediated
by nucleoside diphosphate kinase (NDPK).12 The first phos-
phorylation by dCK is considered the rate-limiting step for
dFdCDP and dFdCTP production.
Gemcitabine can get inactivated through deamination by
cytidine deaminase (CDA), and when in the monophosphate
form by deoxycytidylate deaminase (dCTD). Gemcitabine
may also become inactivated by dephosphorylation of the
monophosphate formby50-nucleotidases (50-NTs), converting
nucleotides back to nucleosides. On the other hand, gemci-
tabine exhibits a unique property called self-potentiation to
enhance its activation. The diphosphate form (dFdCDP) in-
hibits ribonucleotide reductase M1 or M2 (RRM1/RRM2) that
convert CDP to dCDP, leading to depletion of dCTP pools and
facilitating incorporation of dFdCTP into DNA.13Known mechanisms of gemcitabine resistance
One mechanism responsible for gemcitabine resistance is
the dysregulation of the proteins participating in gemcita-
bine metabolism pathways, including deficiency of hENT1,chanisms of gemcitabine resistance. Gemcitabine (dFdC) is a
o become pharmacologically active. Gemcitabine can interrupt
resistance can be either intrinsic or acquired. Resistance can
etabolism enzymes, apoptosis pathway, ABC transporter pro-
Fig. 2 Diagrams of the Hedgehog, Wnt, Notch pathways and their roles for gemcitabine resistance. Hedgehog (Hh), Wnt and
Notch signaling, which regulate embryonic development and somatic stem cells, may be reactivated in gemcitabine-resistant
cancer cells. Elevated expression of the target genes in these pathways may result in inactivation of the apoptosis pathway, high
expression of drug efflux pumps or activation of the cancer stem cells (CSCs), ultimately leading to gemcitabine resistance.
Gemcitabine resistance in cancer 301down-regulation of rate-limiting enzyme dCK, and up-
regulation of RRM1/RRM2.14,15 Hu antigen R (HuR), which
is an RNA-binding protein that post-transcriptionally regu-
lates dCK, is also associated with gemcitabine efficacy.
High levels of HuR correlated with a better overall survival
in gemcitabine-treated patients.16
Another gemcitabine resistance mechanism is high
expression of drug efflux pumps, such as (ABC) transporter
family proteins.17 These proteins are highly expressed in
cancer stemcells (CSCs) and havebeen shown to protect CSCs
from chemotherapeutic agents.18 Recent evidence has sup-
ported the link of gemcitabine resistance and EMTwith stem
cell phenotype.19 In general, therapeutics directed against
CSCs and EMT offer new strategies to chemoresistance.
Gemcitabine resistance is also associated with multiple
genetic and epigenetic abnormalities. Changes in one or a
few genes remain crucial for maintaining drug resistance
cell survival and malignant phenotype. There is evidence to
indicate that NF-kB,20e23 AKT,20,24,25 MAPK,25,26 HIF-
1a27pathways are involved in gemcitabine resistance
in vitro and some in vivo models (Fig. 1). However, the
functional significance of these molecules for gemcitabine
resistance remains largely untested.Relevance of hedgehog signaling to
gemcitabine resistance
As an essential developmental signaling pathway, the Hh
pathway is critical for maintaining tissue polarity andstem cell population. Hedgehog signaling molecules in
mammal include three ligands (Sonic hedgehog-Shh, In-
dian hedgehog-Ihh and Desert hedgehog-Dhh), two re-
ceptors (Patched1-Ptc1, Patched2-Ptc2), a key signal
transducer smoothened (Smo) and three transcription
factors (Gli1, Gli2, Gli3). When ligands are not present,
Smo function is inhibited by another transmembrane
protein (Ptc1, Ptc2). Upon binding of an active Hh ligand,
this inhibitory effect is lifted, allowing Smo to signal
downstream, eventually leading to active transcription of
Gli molecules through binding the specific consensus se-
quences located in the promoter region of target
genes.28,29 Besides these canonical Hh pathways, there
are non-canonical Hh pathways activated directly through
Ptc1 or Smo, or other pathways including the PI3K/AKT
and MEK signaling cascades.30 Dysregulated signaling
through the Hh pathway is implicated in virtually all
human cancers. Furthermore, Hh pathway is now also
recognized as a major driver of resistance to a number of
chemotherapeutical reagents. Smo inhibitors, including
vismodegib (GDC-0449), sonidegib (LDE225), BMS-833923,
PF-04449913, and LY2940680, are being tested in a range
of advanced cancers (NCI Clinical Trail Database (http://
www.clinicaltrials.gov/)). To our disappointment, how-
ever, the Smo inhibitors seem to be ineffective in most
extracutaneous solid tumors.31 Therefore, Smo inhibition
alone may not provide sufficient efficacy in these cancers,
and combinations with other conventional cytotoxic anti-
tumor agents might be needed to achieve maximal
benefit. Currently, several Phase II trials of hedgehog
302 Y. Jia, J. Xiepathway inhibitor vismodegib and Phase I trials of LDE225
in combination with gemcitabine are ongoing (http://
www.clinicaltrials.gov/).
Activation of Hh signaling may not work alone because
cross-talk with other signaling pathways plays critical roles
in gemcitabine resistance. For example, MAP3K10 over-
expression can result in up-regulation of Gli1 and Gli2,
leading to decrease in the gemcitabine sensitivity of in
pancreatic cancer cells.32 Perifosine, a novel Akt inhibitor,
through suppressing Gli1 activation, can enhance
gemcitabine-induced cytotoxicity in pancreatic cancer
cells.33 Lithium synergistically enhances the anti-cancer
effect of gemcitabine, by inhibiting the activity of
glycogen synthase kinase 3b (GSK3b), therefore promoting
the ubiquitin-dependent proteasome degradation of Gli1.34
ABCB2, the drug efflux transporters, serves as the down-
stream target of Shh signaling, and its expression can in-
crease gemcitabine resistance in PDAC cells.35
Understanding how integration of HH signaling with other
pathways and discovery and synthesis of Gli specific in-
hibitors is in great need for effective suppression of non-
canonical Hh signaling in cancer.
Recent reports have also indicated that hedgehog
signaling may be critical for maintaining a small cell popu-
lation with stem cell properties, and thus conferring resis-
tance to chemotherapy. There is evidence to indicate thatHh
signaling regulates expression of several cancer stem cell-
relatedmarkers, such as ALDH1, Bmi1, Snail, Wnt2, PDGFRa,
Jagged-1, CD44 and c-MET.36e42 The level of Hh expression is
often higher in the cancer stem cell population.43e46 Thus,
wehave reasons to believe that inhibition ofHh signalingmay
be effective in reducing the number of cancer stem cells,
which may play an important role for chemotherapy and
radiotherapy resistance. Chloroquine treatment in combi-
nation with gemcitabine significantly decreased CSCs, via
inhibition of hedgehog signaling in the stroma, which sup-
ports CSCs and non-CSCs via a paracrine mechanism.47
Arsenictrioxide (ATO) is described as a SHH inhibitor. Com-
bination treatment of ATO and low dose gemcitabine inhibits
tumor growth, decreases the expression of CD24, CD44, and
aldehyde dehydrogenase 1 family member A1 significantly in
mouse model.48 In response to gemcitabine, both Shh and
CSCs markers as well as EMT regulators are over-expressed,
indicating a protective role of hedgehog signaling against
chemotherapeutic drugs.19 Discovery of a more specific and
complete set of cell surface markers may help to further
characterize CSCs, and the role that Hh pathway played in
drug resistance and the in-depth mechanism require further
systemic studies.The role of Wnt signaling for gemcitabine
resistance
The Wnt signaling pathway controls and regulates crucial
aspects of development, cell proliferation, survival and
polarity.49 Wnts are a family of 19 secreted glycoproteins,
binding to a number of 7-transmembrane receptors of the
Frizzled (FZD) family.50 These receptors transduce signal to
several intracellular proteins, such as Dishevelled (Dsh),
glycogen synthase kinase-3b (GSK-3), Axin, Adenomatous
Polyposis Coli (APC), and b-Catenin. To date, majorsignaling branches have been identified including the ca-
nonical Wnt/b-Catenin pathway, the non-canonical planar
cell polarity pathway, and the non-canonical Wnt/calcium
pathway. These pathways are being actively dissected at
the molecular and biochemical levels. When FZD co-
operates with LRP5/6 (low-density lipoprotein receptor-
related proteins 5 and 6), the canonical Wnt/b-Catenin
signaling pathway is activated.51 In the absence of the
activating Wnt signals, b-Catenin is phosphorylated by a
complex of GSK-3b, proteins APC, b-TRCP and Axin. Non-
canonical Wnt signaling can phosphorylate small G-pro-
teins and JNK to transmit the signal to the nucleus, or
release calcium affecting Nemo-like kinase (NLK) or nuclear
factor of activated T-cells (NFAT).52
Emerging evidence indicates that activation of the Wnt
pathway is involved in cancer development and drug
resistance. Wnt/b-Catenin signaling is activated in gemci-
tabine-resistant lung cancer cell lines.53 WNT5A expression
leads to resistance to gemcitabine-induced apoptosis in a
xenograft model of pancreatic ductal adenocarcinoma
(PDAC).54 The heparan sulfate mimetic PG545 in combina-
tion with gemcitabine exerts anti-tumor activity by dis-
rupting Wnt/b-Catenin signaling.55 Masitinib, a tyrosine
kinase inhibitor, can sensitize gemcitabine treatment
through down-regulation of the Wnt/b-Catenin signaling
pathway in pancreatic cancer cell lines, which is further
confirmed in a Phase II clinical study.56 These therapeutic
approaches to target upstream or downstream of Wnt
signaling pathway indicate that combination therapy may
be required to effectively treat gemcitabine-resistant
malignancies.
Recent reports have implicated Wnt pathway may be
especially important in maintaining the subpopulation of
cancer cells with stem cell properties as well as conferring
resistance to chemotherapies. Wnt signaling is increased in
pancreatic cancer side population (SP) cells. Furthermore,
when cultured with increasing concentrations of gemcita-
bine, the proportion of SP cells were significantly
enriched.57 EMT has been implicated as a drug resistance
mechanism, allowing tumor cells to escape from cytotoxic
and pathway targeted therapies. Activation of Wnt
signaling up-regulates the EMT activator ZEB1 and de-
termines response to gemcitabine in mantle cell lym-
phoma.58 It will be important for future research to unravel
the interconnectedness of Wnt pathway with CSCs and EMT
in gemcitabine resistance.The Notch pathway regulates cancer stem cells
in gemcitabine resistance
It has been well known that Notch signaling plays important
roles for regulating cellecell communication, cell prolif-
eration, differentiation and apoptosis. Activation of Notch
receptors (Notch-1e4) is often achieved by canonical li-
gands, Delta-like ligands (DLLs) 1, 3 and 4, and Jagged li-
gands 1 and 2. The binding of ligandereceptor results in g-
secretase-mediated cleavage and nuclear localization of its
intracellular domain to regulate notch-specific gene
expression.59
Evidence suggests that Notch signaling may play a crucial
role in the tumor progression and possibly therapy-
Gemcitabine resistance in cancer 303resistance.60,61 Notch-2 and Jagged-1 are highly up-
regulated in gemcitabine-resistant pancreatic cancer
cells.62 Notch-3 mRNA expression is predicted to be the key
predictive biomarker for gemcitabine effect and sensitivity
in pre-treatment endoscopic ultrasound-guided fine-needle
aspiration (EUS-FNA) samples from patients with PDC.63
Inhibition of Notch-1 by siRNA enhances the sensitivity to
gemcitabine in pancreatic cancer through activating
apoptosis activity.64 Midkine (MK)eNotch-2 interaction in-
creases Notch signaling, elevates EMT, and is associated
with gemcitabine resistance.65 Moreover, inhibition of
Notch-3 enhances the sensitivity to gemcitabine in
pancreatic cancer through inactivation of the PI3K/Akt-
dependent pathway.66 The g-secretase inhibitors DAPT
and MRK003 effectively inhibit intra-tumoral Notch
signaling in PDA, leading to a remarkable increase in che-
mosensitivity to gemcitabine.67,68
Emerging evidence clearly shows that abnormal Notch
signaling may contribute to carcinogenesis by deregulating
the self-renewal of normal stem cells. Inappropriate acti-
vation of Notch signaling could be an early event leading to
accumulation of undifferentiated precursor cells in
pancreatic cancers.69 MRK-003, g-secretase inhibitor,
treatment results in down-regulation of nuclear Notch-1
intracellular domain, and a decrease in tumor-initiating
cells that are capable of extensive self-renewal.70
Furthermore, the proportion of CD24þCD44þ CSCs in
pancreatic cancer cells line increased after gemcitabine
treatment and this increase was mediated by the Notch
pathway.71 A Notch signaling pathway inhibitor (L1790) and
Hes-1 siRNA are shown to reverse the chemoresistance
induced by PSCs.72 Neutralizing antibodies against human
DLL4 reduces the percentage of CSC in gemcitabine-
resistant mouse model.73 Through down-regulation ofTable 1 Summary of combination therapies and their mechanis
Pathway Target Compound Mechanism of action
Hh Smo Vismodegib,
LDE225
Phase II trials of vismodegib a
are ongoing (http://www.clin
Chloroquine Chloroquine treatment in com
inhibition of hedgehog signal
Gli1 Perifosine Perifosine, an Akt inhibitor, t
induced cytotoxicity in pancr
Lithium By inhibiting the activity of g
ubiquitin-dependent proteaso
SHH Arsenic trioxide
(ATO)
Combination treatment of AT
the expression of CD24, CD44
significantly in mouse model.
Wnt b-
Catenin
PG545 PG545 in combination with g
Catenin signaling.55
Masitinib Masitinib, a tyrosine kinase in
regulation Wnt/b-Catenin sig
Notch g-
secretase
DAPT, MRK003 DAPT and MRK003 effectively
remarkable decrease in chem
L1790 L1790 are shown to reverse t
DLL4 Neutralizing
antibodies
Neutralizing antibodies again
resistant mouse model.73
Notch-1 Sulforaphane
(SF)
Through down-regulation of N
selection of ALDH1 positive cNotch-1, Sulforaphane (SF) prevented gemcitabine-induced
selection of ALDH-positive cells.74 As indicated above,
Notch signaling may be a promising target to overcome
gemcitabine resistance.
Cross-talk among signaling pathways
Cross-talks among Hh, Notch or Wnt signaling pathways
have been reported in a variety of cancer cells. The tran-
scription of Jagged-2, a Notch ligand, can be up-regulated
in response to Hh pathway activation.75 Whereas Wnt/b-
Catenin can activate Jagged-1,76 Wnt-1 induces trans-
formation and tumorigenesis in human mammary epithelial
cells, through up-regulation of Notch pathway. Notch and
Hh signaling both can activate Hes-1.77 On the other hand,
Hh signaling is found to inhibit Wnt signaling via up-
regulation of Wnt-inhibitory factor sFRP1, and to suppress
b-Catenin transcriptional activity.78 CK1 and GSK3, the core
component of the Wnt pathway, regulate Gli1 proteolytic
processing.79 Therefore, combination therapies targeting
more than one pathway in cancer may be more effective.
Hh may modulate the tumorigenic property in cooperation
with Notch in breast cancer. Phase I and Phase Ib/II trials,
combining Hh pathway inhibitor vismodegib and Notch
pathway inhibitor RO4929097 are being conducted in pa-
tients with breast cancer and sarcoma (http://www.
clinicaltrials.gov).
Conclusions and future directions
Gemcitabine still has clinical potential to treat a broad
spectrum of human cancers, but resistance is probably the
major impediment to achieve satisfactory clinicalm in regulation gemcitabine resistance.
nd Phase I trials of LDE225 in combination with gemcitabine
icaltrials.gov/).
bination with gemcitabine significantly decreased CSCs, via
ing in the stroma.47
hrough suppressing Gli1 activation, can enhance gemcitabine-
eatic cancer cells33
lycogen synthase kinase 3b (GSK3b), therefore promoting the
me degradation of Gli1.34
O and low dose gemcitabine inhibits tumor growth, decreases
, and aldehyde dehydrogenase 1 family member A1
48
emcitabine exerts anti-tumor activity by disrupting Wnt/b-
hibitor, can sensitize gemcitabine treatment through down-
naling pathway.56
inhibit intratumoral Notch signaling in PDA, leading to a
osensitivity to gemcitabine67,68
he gemcitabine resistance induced by PSCs.72
st human DLL4 reduces the percentage of CSC in gemcitabine-
otch-1, Sulforaphane (SF) prevented gemcitabine-induced
ells74
304 Y. Jia, J. Xieoutcomes. As evident in the numerous studies, targeting
developmental pathways is quite promising to improve
gemcitabine efficacy in cancer (Table 1).
There are a number of challenges in overcoming gem-
citabine resistance. First, the mechanism of gemcitabine
resistance is still largely unknown. Inhibition of a single
signaling pathway is unlikely to result in a substantial
improvement in gemcitabine resistance, owing to the cross-
talk from various pathways. Second, despite exciting data
in various tumor and their disease models, it is still too
early to know whether any of these therapeutic agents that
specifically target the developmental pathway will be
efficacious with an acceptable safety profile. Third, further
studies are urgently needed to confirm the relevance of
these developmental signaling pathways to gemcitabine
resistance and to find reasonable combination for therapy.
Despite these future challenges, targeting Hh, Notch and
Wnt signaling pathways to improve the gemcitabine treat-
ment outcome in cancer patients is clearly the way for
future studies.
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